KEYNOTE-A39 : NCT04223856: Phase 3: Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)
First Posted 2020-01-10 Trial status Active, not recruiting Sponsor Astellas Pharma Global Development, Inc. Abstract Presentation Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer ESMO - 11 Mar 2024 Click here for details Peer-reviewed journal publication Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer March 6, 2024 - N Engl J
Dec 15, 2023